1. Home
  2. SYNX vs APM Comparison

SYNX vs APM Comparison

Compare SYNX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.16

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

N/A

Current Price

$0.85

Market Cap

7.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SYNX
APM
Founded
2005
2010
Country
Israel
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.3M
IPO Year
2023
2018

Fundamental Metrics

Financial Performance
Metric
SYNX
APM
Price
$1.16
$0.85
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
91.8K
20.7K
Earning Date
05-01-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$32.35
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$0.65
52 Week High
$2.15
$4.47

Technical Indicators

Market Signals
Indicator
SYNX
APM
Relative Strength Index (RSI) 47.97 48.11
Support Level $0.93 $0.75
Resistance Level $1.34 $0.89
Average True Range (ATR) 0.07 0.06
MACD -0.01 0.00
Stochastic Oscillator 40.00 44.11

Price Performance

Historical Comparison
SYNX
APM

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: